Form 8-K - Current report:
SEC Accession No. 0001437749-26-024041
Filing Date
2026-07-22
Accepted
2026-07-22 08:00:09
Documents
13
Period of Report
2026-07-22
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K mnpr20260721_8k.htm   iXBRL 8-K 30216
2 EXHIBIT 99.1 ex_991049.htm EX-99.1 12543
  Complete submission text file 0001437749-26-024041.txt   176754

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mnpr-20260722.xsd EX-101.SCH 3579
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mnpr-20260722_def.xml EX-101.DEF 11424
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE mnpr-20260722_lab.xml EX-101.LAB 15310
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mnpr-20260722_pre.xml EX-101.PRE 11584
16 EXTRACTED XBRL INSTANCE DOCUMENT mnpr20260721_8k_htm.xml XML 2846
Mailing Address 1000 SKOKIE BLVD SUITE 350 WILMETTE IL 60091
Business Address 1000 SKOKIE BLVD SUITE 350 WILMETTE IL 60091 8473880349
Monopar Therapeutics (Filer) CIK: 0001645469 (see all company filings)

EIN.: 320463781 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39070 | Film No.: 261191681
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)